How Eli Lilly Became a $1 Trillion Company
Speakers
Summary
Bloomberg documentary examines how Eli Lilly grew into a trillion-dollar pharmaceutical company on the back of GLP-1 weight-loss drugs Mounjaro and Zepbound, its massive manufacturing investments, and its pipeline including retatrutide, while also highlighting the challenge of sustaining such success amid patent cliffs and competition.
- Lilly's market cap surged from ~$100B to over $1T in a decade.
- GLP-1 drugs Mounjaro and Zepbound are the key drivers.
- Manufacturing investment of $27B solved shortages and secured supply chain.
- Lilly has separated itself from rival Novo Nordisk in revenue.
- Next pipeline hope is retatrutide, a triple-hormone drug with 30% weight loss in studies.
- Company is expanding into gene therapy, neuroscience, immunology, and cancer.
- AI partnership with Nvidia provides advanced computing for drug discovery, but no new drugs from AI yet.
- Key question is whether Lilly can avoid the boom-bust cycle typical of pharma blockbusters.
Ideas
Lilly's GLP-1 drugs and manufacturing scale.
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound, combined with massive manufacturing investments totaling $27 billion in one year, have addressed shortages and created a dominant market position, separating it from pioneer Novo Nordisk and driving its valuation to over a trillion dollars, supporting continued growth.
Up Next
This Bloomberg Markets video, published June 23, 2026, features Narrator discussing LLY. 1 trade idea extracted by AI with direction and confidence scoring.